

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sipai Health Technology Co., Ltd. 思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 0314)

VOLUNTARY ANNOUNCEMENT

SHARE PURCHASE PURSUANT TO THE 2023 SHARE AWARD SCHEME

Reference is made to the announcement (the “**Announcement**”) of Sipai Health Technology Co., Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) dated August 30, 2023 in relation to, among others, the adoption of the 2023 share award scheme (the “**Scheme**”) by the board (the “**Board**”) of directors (the “**Directors**”) of the Company. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company was informed by the Trustee that, during the period from October 31, 2023 to January 18, 2024, the Trustee has purchased 12,715,200 Shares in aggregate on the market at the total consideration of approximately HK\$94,884,012, ranged from approximately HK\$6.37 per Share to approximately HK\$8.97 per Share pursuant to the Scheme Rules (for the avoidance of doubt, including the 5,514,000 Shares purchased during the period from October 31, 2023 to November 29, 2023, details of which were set out in the announcement of the Company dated November 29, 2023). The underlying Shares are held on trust for the benefit of the Eligible Participants. As of the date of this announcement, the Trustee has purchased a total of 12,715,200 Shares pursuant to the Scheme Rules, representing approximately 1.67% of the total number of Shares of the Company in issue as at the date of this announcement. The Shares so purchased will be used as Awards for the Eligible Participants under the Scheme to incentivize them to make contribution to the Group.

The Trustee will continue to purchase the Shares on the market pursuant to the rules of the Scheme. The Company will comply with the Listing Rules when it decides to grant any Award pursuant to the Scheme in the future.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, January 22, 2024

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. CHANG Stanley Yi (張翊, alias張翌軒), Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.